• In April 2026, Delek US Holdings, Inc. amended its Third Amended and Restated Credit Agreement, lifting its revolving loan commitments from US$1,100.0 million to US$1,250.0 million, extending the facility’s maturity to April 9, 2031, trimming interest margins by 0.25%, and revising key covenant thresholds and reporting requirements.
• The amendment also expands potential incremental borrowing capacity and tightens how the minimum 1.00 to 1.00 Fixed Charge Coverage Ratio is tested, signaling an emphasis on greater financial flexibility backed by first‑priority liens on substantially all company assets.
• We’ll now examine how this expanded and extended revolving credit facility shapes Delek US Holdings’ investment narrative and financial flexibility.

Find 60 companies with promising cash flow potential yet trading below their fair value.

Delek US Holdings Investment Narrative Recap

To own Delek US, you need to believe its refining and midstream footprint can translate operational improvements into durable cash generation despite hydrocarbon transition and regulatory uncertainty. The expanded revolving credit facility modestly improves short term financial flexibility, but does not remove the core risks around refining cyclicality, regulatory outcomes on small refinery exemptions, or the company’s still‑recent history of net losses and capital intensive operations.

Among recent announcements, the ongoing share repurchase program stands out next to this larger credit line. Delek has bought back over 21.3 million shares for about US$606.1 million through early 2026, while still posting a small full year 2025 net loss of about US$22.8 million. Together with the amended revolver, these moves highlight a balance between returning capital and preserving liquidity at a time when earnings quality and cash coverage of dividends remain key catalysts to watch.

Yet behind this improved liquidity, the risk that Delek’s debt load and hydrocarbon focus could limit future options is something investors should be aware of...

Delek US Holdings' narrative projects $10.3 billion revenue and $1.5 billion earnings by 2028. This implies revenues shrinking by 1.5% per year and an earnings increase of roughly $2.4 billion from -$863.6 million today.

Uncover how Delek US Holdings' forecasts yield a $39.71 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already assuming revenue would shrink about 1.1% a year and no profits for three years, painting a far more pessimistic picture that this new credit flexibility might or might not eventually challenge.

Explore 5 other fair value estimates on Delek US Holdings - why the stock might be worth over 8x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Delek US Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Delek US Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Delek US Holdings' overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.